Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
UNCY Stock Forecast 2026-2027
$6.61
Current Price
$142.06M
Market Cap
Buy 8
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to UNCY Price Targets
+1,261.6%
To High Target of $90.00
+550.5%
To Median Target of $43.00
+217.7%
To Low Target of $21.00
UNCY Price Momentum
+7.0%
1 Week Change
+12.4%
1 Month Change
+7.7%
1 Year Change
+14.6%
Year-to-Date Change
-39.9%
From 52W High of $11.00
+78.2%
From 52W Low of $3.71
📊 TOP ANALYST CALLS
Did UNCY Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Unicycive is one of their latest high-conviction picks.
Latest UNCY Stock Price Targets & Analyst Predictions
Based on our analysis of 10 Wall Street analysts, UNCY has a bullish consensus with a median price target of $43.00 (ranging from $21.00 to $90.00). The overall analyst rating is N/A (N/A/10). Currently trading at $6.61, the median forecast implies a 550.5% upside. This outlook is supported by 8 Buy, 0 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Bruce D. Jackson at Benchmark, suggesting a 217.7% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
UNCY Analyst Ratings
8
Buy
0
Hold
0
Sell
UNCY Price Target Range
Low
$21.00
Average
$43.00
High
$90.00
Current: $6.61
Latest UNCY Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for UNCY.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Oct 29, 2025 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Maintains | $22.00 |
| Sep 15, 2025 | Benchmark | Bruce D. Jackson | Speculative Buy | Maintains | $21.00 |
| May 27, 2025 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Assumes | $9.00 |
| Apr 21, 2025 | Guggenheim | Vamil Divan | Buy | Initiates | $6.00 |
| Apr 11, 2025 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $7.50 |
| Apr 1, 2025 | HC Wainwright & Co. | Ed Arce | Buy | Maintains | $7.50 |
| Jan 29, 2025 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $4.00 |
| Jan 8, 2025 | HC Wainwright & Co. | Ed Arce | Buy | Maintains | $4.00 |
| Nov 22, 2024 | Benchmark | Bruce Jackson | Speculative Buy | Reiterates | $3.00 |
| Nov 14, 2024 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Nov 12, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $2.50 |
| Oct 9, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $2.50 |
| Sep 6, 2024 | Benchmark | Bruce Jackson | Speculative Buy | Reiterates | $3.00 |
| Sep 3, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $2.50 |
| Aug 15, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Maintains | $2.50 |
| Jul 10, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $4.50 |
| Jun 25, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $4.50 |
| Jun 3, 2024 | Benchmark | Bruce Jackson | Speculative Buy | Reiterates | $3.00 |
| May 31, 2024 | Benchmark | Bruce Jackson | Speculative Buy | Reiterates | $3.00 |
| May 29, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $4.50 |
Unicycive Therapeutics Inc. (UNCY) Competitors
The following stocks are similar to Unicycive based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Unicycive Therapeutics Inc. (UNCY) Financial Data
Unicycive Therapeutics Inc. has a market capitalization of $142.06M with a P/E ratio of -1.1x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -102.3%.
Valuation Metrics
Market Cap
$142.06M
Enterprise Value
$83.72M
P/E Ratio
-1.1x
PEG Ratio
0.0x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+30.1%
Current Ratio
3.8x
Debt/Equity
0.7x
ROE
-102.3%
ROA
-44.2%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Unicycive Therapeutics Inc. (UNCY) Business Model
About Unicycive Therapeutics Inc.
What They Do
Develops therapies for kidney disease treatment.
Business Model
The company focuses on creating and commercializing innovative therapies aimed at addressing unmet medical needs in nephrology, with significant emphasis on conditions like hyperphosphatemia in chronic kidney disease. It generates revenue through the development of its drug pipeline, moving candidates from preclinical to clinical stages and potentially bringing them to market.
Additional Information
Unicycive Therapeutics employs advanced drug discovery techniques and collaborates with industry and academic partners to enhance its research capabilities. The company's commitment to science-driven approaches positions it well within the competitive biotechnology landscape, aiming to improve patient outcomes and quality of life.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
22
CEO
Dr. Shalabh K. Gupta M.D., MPA
Country
United States
IPO Year
2021
Website
unicycive.comUnicycive Therapeutics Inc. (UNCY) Latest News & Analysis
Latest News
Unicycive Therapeutics Announces Resubmission of New Drug Application (NDA) for Oxylanthanum Carbonate (OLC)
17 days ago
Quick Summary
A new PDUFA date is anticipated in the first half of 2026, following the resubmission of the NDA within 30 days.
Why It Matters
A new PDUFA date indicates a timeline for potential drug approval, impacting stock valuations and investor sentiment based on expected market entry and revenue potential.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Grabar Law Office is investigating potential fiduciary duty breaches by officers and directors of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) on behalf of shareholders.
Why It Matters
Shareholder investigations can indicate potential legal issues or managerial misconduct at Unicycive Therapeutics, affecting stock performance and investor confidence.
Source: Newsfile Corp
Market Sentiment:
Neutral
Quick Summary
Unicycive Therapeutics (Nasdaq: UNCY) will have CEO Shalabh Gupta participate in two investor events in December 2025, focusing on their kidney disease therapies.
Why It Matters
Unicycive's CEO participating in investor events may signal upcoming developments or data, potentially influencing stock performance and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Unicycive Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update
2 months ago
Quick Summary
Unicycive Therapeutics plans to resubmit its NDA for oxylanthanum carbonate by year-end, showing significant pill burden reduction. It ended Q3 with $42.7 million in cash, funding into 2027.
Why It Matters
Unicycive's resubmission of the NDA for OLC and promising data on reduced pill burden could lead to market approval, enhancing revenue potential and attracting investor interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Unicycive Therapeutics, Inc. (Nasdaq: UNCY) will have CEO Shalabh Gupta participate in a fireside chat at the Guggenheim Healthcare Innovation Conference on November 10, 2025, at 3:30 p.m. ET.
Why It Matters
Shalabh Gupta's participation in a prominent healthcare conference may enhance visibility for Unicycive, potentially attracting investors and influencing stock performance in the biotech sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Unicycive's defendants reportedly exaggerated the company's FDA readiness for its OLC NDA, leading to cGMP issues and subsequent FDA delays, which caused stock declines.
Why It Matters
Unicycive's overstated FDA readiness and subsequent compliance issues may lead to delays in product approval, negatively impacting stock value and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About UNCY Stock
What is Unicycive Therapeutics Inc.'s (UNCY) stock forecast for 2026?
Based on our analysis of 10 Wall Street analysts, Unicycive Therapeutics Inc. (UNCY) has a median price target of $43.00. The highest price target is $90.00 and the lowest is $21.00.
Is UNCY stock a good investment in 2026?
According to current analyst ratings, UNCY has 8 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $6.61. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for UNCY stock?
Wall Street analysts predict UNCY stock could reach $43.00 in the next 12 months. This represents a 550.5% increase from the current price of $6.61. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Unicycive Therapeutics Inc.'s business model?
The company focuses on creating and commercializing innovative therapies aimed at addressing unmet medical needs in nephrology, with significant emphasis on conditions like hyperphosphatemia in chronic kidney disease. It generates revenue through the development of its drug pipeline, moving candidates from preclinical to clinical stages and potentially bringing them to market.
What is the highest forecasted price for UNCY Unicycive Therapeutics Inc.?
The highest price target for UNCY is $90.00 from at , which represents a 1,261.6% increase from the current price of $6.61.
What is the lowest forecasted price for UNCY Unicycive Therapeutics Inc.?
The lowest price target for UNCY is $21.00 from Bruce D. Jackson at Benchmark, which represents a 217.7% increase from the current price of $6.61.
What is the overall UNCY consensus from analysts for Unicycive Therapeutics Inc.?
The overall analyst consensus for UNCY is bullish. Out of 10 Wall Street analysts, 8 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $43.00.
How accurate are UNCY stock price projections?
Stock price projections, including those for Unicycive Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 15, 2026 6:19 PM UTC